Y
Yoshihisa Kobayashi
Researcher at Kindai University
Publications - 85
Citations - 2690
Yoshihisa Kobayashi is an academic researcher from Kindai University. The author has contributed to research in topics: Lung cancer & Erlotinib. The author has an hindex of 29, co-authored 74 publications receiving 2174 citations. Previous affiliations of Yoshihisa Kobayashi include University of California, San Diego & University of Tokyo.
Papers
More filters
Journal ArticleDOI
Not all epidermal growth factor receptor mutations in lung cancer are created equal: Perspectives for individualized treatment strategy
TL;DR: For the further development of targeted therapy in all EGFR mutations, it is important to precisely detect targetable mutations, to select the most appropriate TKI for each mutation, and to continue investigating in vitro studies and collecting clinical data on even rare mutations.
Journal ArticleDOI
EGFR Exon 18 Mutations in Lung Cancer: Molecular Predictors of Augmented Sensitivity to Afatinib or Neratinib as Compared with First- or Third-Generation TKIs
Yoshihisa Kobayashi,Yosuke Togashi,Yasushi Yatabe,Hiroshi Mizuuchi,Park Jangchul,Chiaki Kondo,Masaki Shimoji,Katsuaki Sato,Kenichi Suda,Kenji Tomizawa,Toshiki Takemoto,Toyoaki Hida,Kazuto Nishio,Tetsuya Mitsudomi +13 more
TL;DR: Patients with lung cancers harboring G719X exhibited higher response rate to afatinib or neratinib (∼80%) than to 1G TKIs (35%–56%) by compilation of data in the literature.
Journal ArticleDOI
Clinical and pathologic features of lung cancer expressing programmed cell death ligand 1 (PD-L1).
Masaki Shimoji,Shigeki Shimizu,Katsuaki Sato,Kenichi Suda,Yoshihisa Kobayashi,Kenji Tomizawa,Toshiki Takemoto,Tetsuya Mitsudomi +7 more
TL;DR: PD-L1 expression was associated with high proliferative activity and the EMT phenotype in adenocarcinoma but not in squamous cell carcinoma of the lung, and was a significant poor prognostic factor in patients with lung adenOCarcinomas.
Journal ArticleDOI
Management of ground-glass opacities: should all pulmonary lesions with ground-glass opacity be surgically resected?
TL;DR: It remains unclear whether all pulmonary lesions with GGO should be surgically resected or whether lesions without changes may not require resection, and future studies on the genetic differences between GGOs with growth and those without growth will help establish an appropriate management algorithm.
Journal ArticleDOI
Clinicoradiologic characteristics of patients with lung adenocarcinoma harboring EML4-ALK fusion oncogene
Takayuki Fukui,Yasushi Yatabe,Yoshihisa Kobayashi,Kenji Tomizawa,Simon Ito,Shunzo Hatooka,Keitaro Matsuo,Tetsuya Mitsudomi +7 more
TL;DR: In this paper, the authors explored the EML4-ALK gene in a relatively large cohort and reviewed the clinicoradiologic background of the patients with lung adenocarcinoma.